Everett E. Vokes

About

Everett E. Vokes, MD, is the John E. Ultmann Distinguished Service Professor and Chair of the Department of Medicine at the University of Chicago, as well as physician-in-chief at the University of Chicago Medicine. He earned his medical degree at the University of Bonn Medical School in Germany and completed his clinical training in Australia and the United States, including a fellowship in hematology-oncology at the University of Chicago. Dr. Vokes is a clinical and translational investigator focusing on the biology and treatment of lung and head and neck cancers, with particular interest in the interaction of chemotherapy and radiation, as well as the integration of targeted and immune-based agents. He has established the clinical and intellectual basis for national trials investigating concomitant chemoradiotherapy and multispecialty care approaches, leading clinical and translational research both at the university and nationally. Dr. Vokes is a member of several professional organizations, including the American Society of Clinical Oncology, the American Association for Cancer Research, and the International Association for the Study of Lung Cancer. He is an elected member of the American Society of Clinical Investigation and the American Association of Professors, and serves on editorial boards of multiple oncology journals. His prolific publication record includes over 80 book chapters and 500 papers in prominent journals, and he has presented his work at numerous…

Research topics

• Internal medicine
• Oncology
• Medicine
• Radiology
• Biology
• Chemistry
• Nuclear medicine
• Immunology
• Cancer research
• Surgery

Selected publications

• Lobar or Sublobar Resection for Peripheral Stage IA Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2023-02-08 · 1004 citations

  articleOpen accessSenior author

  BACKGROUND: The increased detection of small-sized peripheral non-small-cell lung cancer (NSCLC) has renewed interest in sublobar resection in lieu of lobectomy. METHODS: We conducted a multicenter, noninferiority, phase 3 trial in which patients with NSCLC clinically staged as T1aN0 (tumor size, ≤2 cm) were randomly assigned to undergo sublobar resection or lobar resection after intraoperative confirmation of node-negative disease. The primary end point was disease-free survival, defined as the…

  PublisherOA PDFDOI

• Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2021-01-15 · 656 citations

  articleOpen access

  PURPOSE: Immunotherapy has revolutionized the treatment of advanced non-small-cell lung cancer (NSCLC). In two phase III trials (CheckMate 017 and CheckMate 057), nivolumab showed an improvement in overall survival (OS) and favorable safety versus docetaxel in patients with previously treated, advanced squamous and nonsquamous NSCLC, respectively. We report 5-year pooled efficacy and safety from these trials. METHODS: once every 3 weeks) until progression or unacceptable toxicity. The primary en…

  PublisherDOI

• High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538

  Journal of Clinical Oncology · 2023 · 90 citations

  Senior authorCorresponding

  PURPOSE: Although level 1 evidence supports 45-Gy twice-daily radiotherapy as standard for limited-stage small-cell lung cancer, most patients receive higher-dose once-daily regimens in clinical practice. Whether increasing radiotherapy dose improves outcomes remains to be prospectively demonstrated. METHODS: This phase III trial, CALGB 30610/RTOG 0538 (ClinicalTrials.gov identifier: NCT00632853), was conducted in two stages. In the first stage, patients with limited-stage disease were randomly…

  DOI

• Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade

  Nature Cancer · 2022 · 90 citations

  PublisherDOI

• Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors

  Clinical Cancer Research · 2021 · 42 citations

  PURPOSE: CD137 agonism and CSF1R blockade augment stereotactic body radiotherapy (SBRT) and anti-programmed death-1 in preclinical models. We evaluated the safety and efficacy of SBRT with nivolumab+urelumab (CD137 agonist) or nivolumab+cabiralizumab (CSF1R inhibitor). PATIENTS AND METHODS: This phase I clinical trial enrolled patients with advanced solid tumors that had progressed on standard therapies. SBRT was delivered to 1-4 metastases with nivolumab+urelumab or nivolumab+cabiralizumab give…

  PublisherDOI

Recent grants

• NIH Grant P50DE011921

  NIH · $8.6M · 2002

• NIH Grant U01CA063187

  NIH · $2.1M · 2001

Frequent coauthors

• Ezra E.W. Cohen

  Tempus Labs (United States)

  487 shared

• Daniel J. Haraf

  University of Chicago

  454 shared

• James E. Herndon

  Duke University

  324 shared

• Ravi Salgia

  City of Hope

  291 shared

• Ralph R. Weichselbaum

  University of Chicago

  282 shared

• Kerstin Stenson

  268 shared

• Waun Ki Hong

  242 shared

• Jay S. Cooper

  R&D Systems (United States)

  235 shared

Awards & honors

• Elected member of the American Society of Clinical Investiga…
• Elected member of the American Association of Professors